Recent studies report remarkable immunotherapy responses in subsets of pancreatic cancer patients treated solely with immune checkpoint inhibitors, exhibiting unprecedented progression-free survival and durable tumor shrinkage. Concurrently, pioneering dual immunotherapy combining nivolumab and ipilimumab for advanced hepatocellular carcinoma has gained regulatory approvals globally, improving survival outcomes. These immunotherapeutic breakthroughs represent important strides against historically refractory cancers, expanding treatment options and prompting further clinical development efforts.